Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Things are moving quickly at Blueprint Medicines. | As it looks to fulfill the potential of newly approved Ayvakit, Blueprint Medicines has promoted two people to its C-Suite. Philina Lee, Ph.D ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.

An update from BB Biotech ( ($CH:BION) ) is now available. In Q2 2025, BB Biotech outperformed the Nasdaq Biotech Index, with a 10.2% increase in ...

--Blueprint Medicines Corporation today announced that the European Medicines Agency has validated the company's Type II variation marketing authorization application for AYVAKYT ® for the ...

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, ...

--Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to report data presentations ...

Paris: Sanofi has announced the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a ...

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025 . Sanofi today announces the completion of its ...

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation ( ...